Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
new york blog main
6
×
boston blog main
boston top stories
biotech
clinical trials
new york top stories
san diego blog main
boston
drugs
san diego top stories
san francisco blog main
akcea therapeutics
cancer
gene therapy
inotersen
new york
patisiran
regeneron pharmaceuticals
san francisco top stories
startups
tafamidis
accelerator
adeno-associated virus
airbnb
alnylam pharmaceuticals
amarin
amazon web services (aws)
anylam pharmaceuticals
artificial intelligence (a.i.)
astellas pharma
athelas
atlas venture
atomwise
attack
audentes therapeutics
avidity biosciences
barry greene
What
ago
6
×
medicines
alnylam
big
biotechs
drug
fda
genetic
patients
rare
therapeutics
years
abuzz
adding
admits
aiming
akcea
amarin
amyloidosis
approve
approved
attr
available
awaits
balance
battle
biological
build
classes
clinical
combinator
community
companies
considering
crossed
data
debilitating
decades
decibel
decision
Language
unset
Current search:
ago
×
" new york blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision